Actinic Keratosis Market to Witness Transformational Growth Opportunities by 2036 – DelveInsight | Almirall, Biofrontera Pharma, Vidac Pharma, Rubedo Life Sciences, Bausch Health, Sandoz Pharma

Posted on
by

Actinic Keratosis Market to Witness Transformational Growth Opportunities by 2036 – DelveInsight | Almirall, Biofrontera Pharma, Vidac Pharma, Rubedo Life Sciences, Bausch Health, Sandoz Pharma
The Key Actinic Keratosis Companies in the market include – Almirall, Biofrontera Pharma GmbH, Vidac Pharma, Rubedo Life Sciences, Bausch Health Companies, Sandoz Pharmaceuticals, Athenex/ Almirall, Vidac Pharma, G&E Herbal Biotechnology, Vidac Pharma, DFB Soria, LLC, Coegin Pharma AB, and others.

 

The Actinic Keratosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Actinic Keratosis pipeline products will significantly revolutionize the Actinic Keratosis market dynamics.

 

DelveInsight’s “Actinic Keratosis Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Actinic Keratosis, historical and forecasted epidemiology as well as the Actinic Keratosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

The Actinic Keratosis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2022 to 2036. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

 

Get a Free sample for the Actinic Keratosis Market Report:

https://www.delveinsight.com/report-store/actinic-keratosis-market

 

Some of the key facts of the Actinic Keratosis Market Report:

  • The Actinic Keratosis market size is anticipated to grow with a significant CAGR during the study period (2022-2036).

  • In February 2026, Vidac Pharma announced that the first patient had been successfully enrolled and dosed in its Phase IIb clinical study evaluating VDA-1102 for the treatment of highly proliferative lesions of actinic keratosis.

  • In December 2025, Vidac Pharma announced the initiation of its Phase IIb clinical trial evaluating a novel targeted therapeutic approach for the treatment of highly proliferative lesions of actinic keratosis with its tuvatexib (VDA1102) ointment. This milestone follows receipt of clearance from the European Medicines Agency (EMA) to proceed with the study.

  • In September 2025, Vidac Pharma announced the submission of a Clinical Trial Application (CTA) to the EMA for a new interventional study focused on advanced actinic keratosis lesions.

  • In September 2025, Rubedo Life Sciences announced that the US FDA cleared the Investigational New Drug (IND) application for a Phase Ib/IIa clinical study of its lead candidate RLS-1496 in patients with actinic keratosis.

  • Photosensitizing agents: Aminolevulinic acid hydrochloride is a porphyrin precursor used in photodynamic therapy that selectively accumulates in dysplastic cells and, upon light activation, generates reactive oxygen species that destroy precancerous keratinocytes while sparing surrounding healthy tissue.

  • GPX4 modulators: RLS-1496, belongs to a novel class of adaptive senotherapeutics designed to modulate GPX4 activity and selectively eliminate senescent and dysfunctional cells.

  • Actinic keratosis is more prevalent in men and older populations.

  • The United States represented the largest patient pool among the 7MM, accounting for the majority of diagnosed cases.

  • Actinic keratosis has a higher prevalence in fair-skinned individuals.

  • Among EU4 and the UK, Germany had the highest number of prevalent cases of actinic keratosis in 2025

  • Key Actinic Keratosis Companies: Almirall, Biofrontera Pharma GmbH, Vidac Pharma, Rubedo Life Sciences, Bausch Health Companies, Sandoz Pharmaceuticals, Athenex/ Almirall, Vidac Pharma, G&E Herbal Biotechnology, Vidac Pharma, DFB Soria, LLC, Coegin Pharma AB, and others

  • Key Actinic Keratosis Therapies: Tirbanibulin (KLISYRI), Aminolevulinic acid hydrochloride (AMELUZ), Tuvatexib (VDA-1102), RLS-1496, ALDARA (imiquimod), SOLARAZE (diclofenac topical gel), KLISYRI (tirbanibulin/KX01/ KX2-391), VDA-1102, SR-T100 Gel, Tuvatexib (VDA-1102), SOR-007, AVX-001, and others

  • The Actinic Keratosis epidemiology based on gender analyzed that Actinic Keratosis prevalence is higher among men than women of the same age. In Northern European and North American whites, AKs are uncommon before the age of 40 years

 

Actinic Keratosis Overview

Actinic keratosis is a common precancerous skin condition caused by prolonged sun exposure or tanning bed use. It appears as rough, scaly patches on the skin, often on sun-exposed areas like the face, ears, neck, scalp, chest, backs of hands, forearms, or lips. AK is typically red or pink but can also be brown, gray, or skin-colored. While most AK lesions do not develop into skin cancer, they can evolve into squamous cell carcinoma if left untreated. Treatment options include cryotherapy, topical medications, laser therapy, and other procedures aimed at removing or destroying the abnormal cells.

 

To Know in detail about the Actinic Keratosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Actinic Keratosis Market Forecast

 

Actinic Keratosis Market

The dynamics of the Actinic Keratosis market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2022-2036.

“Increasing Prevalence of disease and growing consumer awareness, will fuel the Actinic Keratosis (AK) market”

 

Actinic Keratosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Actinic Keratosis Epidemiology Segmentation:

The Actinic Keratosis market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

  • Total Prevalent Cases of Actinic Keratosis

  • Total Diagnosed Prevalent Cases of Actinic Keratosis

  • Age-specific Cases of Actinic Keratosis

  • Gender-specific Cases of Actinic Keratosis

  • Total Treated Cases of Actinic Keratosis

 

Download the report to understand which factors are driving Actinic Keratosis epidemiology trends @ Actinic Keratosis Epidemiological Insights

 

Actinic Keratosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Actinic Keratosis market or expected to get launched during the study period. The analysis covers Actinic Keratosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Actinic Keratosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Actinic Keratosis Therapies and Key Companies

  • Tirbanibulin (KLISYRI): Almirall

  • Aminolevulinic acid hydrochloride (AMELUZ): Biofrontera Pharma GmbH

  • Tuvatexib (VDA-1102): Vidac Pharma

  • RLS-1496: Rubedo Life Sciences

  • ALDARA (imiquimod): Bausch Health Companies

  • SOLARAZE (diclofenac topical gel): Sandoz Pharmaceuticals

  • KLISYRI (tirbanibulin/KX01/ KX2-391): Athenex/ Almirall

  • VDA-1102: Vidac Pharma

  • SR-T100 Gel: G&E Herbal Biotechnology

  • Tuvatexib (VDA-1102): Vidac Pharma

  • SOR-007: DFB Soria, LLC

  • AVX-001: Coegin Pharma AB

 

To know more about Cystinosis treatment, visit @ Actinic Keratosis Medications

 

Actinic Keratosis Market Drivers

  • Rising prevalence of actinic keratosis due to increasing exposure to ultraviolet (UV) radiation and aging populations.

  • Growing awareness regarding the risk of progression from actinic keratosis to skin cancer, leading to earlier diagnosis and treatment.

  • Increasing incidence of skin disorders associated with prolonged sun exposure, particularly in regions with high UV intensity.

  • Advancements in treatment options, including topical therapies, photodynamic therapy, and minimally invasive procedures.

  • Expanding healthcare infrastructure and improved access to dermatological services in emerging economies.

 

Actinic Keratosis Market Barriers

  • High treatment costs associated with advanced therapies and repeated treatment sessions.

  • Limited awareness and underdiagnosis of actinic keratosis in developing and underserved regions.

  • Side effects and discomfort associated with certain treatment modalities, affecting patient compliance.

  • Availability of alternative treatment approaches and variations in physician treatment preferences.

  • Stringent regulatory requirements for approval of new dermatological therapies.

 

Scope of the Actinic Keratosis Market Report

  • Study Period: 2022–2036

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Actinic Keratosis Companies: Almirall, Biofrontera Pharma GmbH, Vidac Pharma, Rubedo Life Sciences, Bausch Health Companies, Sandoz Pharmaceuticals, Athenex/ Almirall, Vidac Pharma, G&E Herbal Biotechnology, Vidac Pharma, DFB Soria, LLC, Coegin Pharma AB, and others

  • Key Actinic Keratosis Therapies: Tirbanibulin (KLISYRI), Aminolevulinic acid hydrochloride (AMELUZ), Tuvatexib (VDA-1102), RLS-1496, ALDARA (imiquimod), SOLARAZE (diclofenac topical gel), KLISYRI (tirbanibulin/KX01/ KX2-391), VDA-1102, SR-T100 Gel, Tuvatexib (VDA-1102), SOR-007, AVX-001, and others

  • Actinic Keratosis Therapeutic Assessment: Actinic Keratosis current marketed and Actinic Keratosis emerging therapies

  • Actinic Keratosis Market Dynamics: Actinic Keratosis market drivers and Actinic Keratosis market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Actinic Keratosis Unmet Needs, KOL’s views, Analyst’s views, Actinic Keratosis Market Access and Reimbursement

 

Discover more about therapies set to grab major Actinic Keratosis market share @ Actinic Keratosis Treatment Landscape

 

Table of Contents

1. Actinic Keratosis Market Report Introduction

2. Executive Summary for Actinic Keratosis

3. SWOT analysis of Actinic Keratosis

4. Actinic Keratosis Patient Share (%) Overview at a Glance

5. Actinic Keratosis Market Overview at a Glance

6. Actinic Keratosis Disease Background and Overview

7. Actinic Keratosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Actinic Keratosis

9. Actinic Keratosis Current Treatment and Medical Practices

10. Actinic Keratosis Unmet Needs

11. Actinic Keratosis Emerging Therapies

12. Actinic Keratosis Market Outlook

13. Country-Wise Actinic Keratosis Market Analysis (2022–2036)

14. Actinic Keratosis Market Access and Reimbursement of Therapies

15. Actinic Keratosis Market Drivers

16. Actinic Keratosis Market Barriers

17. Actinic Keratosis Appendix

18. Actinic Keratosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/